menu
    • menu
    [{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pinetree Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Oral","sponsorNew":"Pinetree Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Pinetree Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"STIC Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pinetree Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Pinetree Therapeutics \/ STIC Investments","highestDevelopmentStatusID":"4","companyTruncated":"Pinetree Therapeutics \/ STIC Investments"}]

    Find Clinical Drug Pipeline Developments & Deals by Pinetree Therapeutics

    Menu

    Pinetree Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pinetree Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Pinetree Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : STIC Investments

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Pinetree Closes $17M Series A to Advance AbReptor™ Protein Degradation Platform

                            Details : . The proceeds will be used to leverage the Company's AbReptor antibody degrader platform to advance its novel multispecific TPD development programs across multiple tumor types.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : STIC Investments

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pinetree Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Pinetree Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : $500.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pinetree Announces Option and Global License Agreement with AstraZeneca for EGFR Degrader

                            Details : Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license Pinetree's preclinical EGFR degrader for global development and commercialization for treating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $45.0 million

                            July 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : $500.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth